Asset Management One Co. Ltd. Purchases 65,805 Shares of Pfizer Inc. $PFE

Key Points

• Asset Management One increased its Pfizer stake by 2.5% in the third quarter, purchasing 65,805 additional shares and bringing its holdings to 2.66 million shares valued at approximately $75.8 million. Institutional investors collectively own 68.36% of Pfizer.
• Pfizer reported quarterly earnings of $0.77 per share, beating the $0.68 consensus estimate, while revenue rose 2.6% year over year to $15.03 billion.
• Pfizer declared a quarterly dividend of $0.43 per share, equivalent to a 5.8% annualized yield. Despite some bullish analyst ratings, the overall analyst consensus remains “Hold,” with a $28.72 price target.

Asset Management One Co. Ltd. lifted its position in Pfizer Inc. (NYSE:PFE - Free Report) by 2.5% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,659,025 shares of the biopharmaceutical company's stock after buying an additional 65,805 shares during the quarter. Asset Management One Co. Ltd.'s holdings in Pfizer were worth $75,835,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the company. Retirement Wealth Solutions LLC increased its position in Pfizer by 144.6% during the third quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 509 shares during the last quarter. Evolution Wealth Management Inc. raised its holdings in Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 566 shares in the last quarter. Keb Asset Management LLC acquired a new stake in shares of Pfizer in the second quarter worth about $26,000. Field & Main Bank acquired a new stake in shares of Pfizer in the second quarter worth about $27,000. Finally, Global Trust Asset Management LLC lifted its position in shares of Pfizer by 126.7% in the first quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company's stock worth $33,000 after buying an additional 650 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

Shares of NYSE:PFE opened at $29.82 on Wednesday. The stock's 50-day moving average is $28.42 and its 200-day moving average is $26.72. The company has a market cap of $169.95 billion, a P/E ratio of 39.23 and a beta of 0.32. Pfizer Inc. has a 52-week low of $23.62 and a 52-week high of $30.44.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.09. The business had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period in the prior year, the firm posted $0.78 EPS. Pfizer's revenue for the quarter was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.94 EPS for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 6th. This represents a $1.72 dividend on an annualized basis and a yield of 5.8%. Pfizer's payout ratio is 226.32%.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on PFE. Scotiabank increased their price objective on Pfizer from $30.00 to $33.00 and gave the company an "outperform" rating in a report on Tuesday, October 6th. Bank of America reduced their target price on Pfizer from $27.00 to $26.00 and set a "neutral" rating for the company in a report on Friday, July 10th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research report on Tuesday, October 13th. HSBC increased their price target on Pfizer from $28.00 to $30.00 and gave the company a "hold" rating in a report on Thursday, September 10th. Finally, Weiss Ratings raised shares of Pfizer from a "hold (c-)" rating to a "hold (c)" rating in a research report on Monday, August 31st. Five equities research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Pfizer has a consensus rating of "Hold" and a consensus price target of $28.72.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: ELREXFIO delivers a Phase 3 win: Pfizer said the MagnetisMM-32 study met its primary endpoint, showing a statistically significant and clinically meaningful progression-free-survival benefit for ELREXFIO in patients with relapsed or refractory multiple myeloma compared with standard regimens. The result could support broader use and future regulatory submissions. Pfizer’s ELREXFIO Phase 3 study
• Positive Sentiment: FDA expands prostate-cancer approval: The FDA approved TALZENNA plus XTANDI for an earlier treatment setting in metastatic prostate cancer with homologous recombination repair gene mutations, including BRCA and non-BRCA mutations. The broader label increases the eligible patient population and commercial opportunity for the combination. TALZENNA and XTANDI FDA approval
• Positive Sentiment: Analysts remain constructive: Scotiabank and Jefferies both issued “Buy” ratings, while market commentary points to the possibility of Pfizer exceeding consensus earnings expectations in its upcoming report. Scotiabank Buy rating

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company's portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.